The DOI matches its Crossref record; 186 of the 187 references it cites were found in a registry or an index.
Pathogenesis of Cholestatic Liver Disease and Therapeutic Approaches
Open accessAbstract
Cholestatic liver disorders are caused by genetic defects, mechanical aberrations, toxins, or dysregulations in the immune system that damage the bile ducts and cause accumulation of bile and liver tissue damage. They have common clinical manifestations and pathogenic features that include the responses of cholangiocytes and hepatocytes to injury. We review the features of bile acid transport, tissue repair and regulation, apoptosis, vascular supply, immune regulation, and cholangiocytes that are associated with cholestatic liver disorders. We now have a greater understanding of the physiology of cholangiocytes at the cellular and molecular levels, as well as genetic factors, repair pathways, and autoimmunity mechanisms involved in the pathogenesis of disease. These discoveries will hopefully lead to new therapeutic approaches for patients with cholestatic liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BA-induced cell stress may occur both at the level of hepatocytes (eg, via BA retention) and cholangiocytes (eg, via toxic bile composition and/or biliary stasis).5 14”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Marzioni, M., Glaser, S. S., Francis, H., Marucci, L., Benedetti, A., Alvaro, D., Taffetani, S., Ueno, Y., Roskams, T., Phinizy, J. L., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.10.002 · Cited by 177
RetractedFitzgerald, M., Hayward, I. P., Thomas, A. C., Campbell, J. H., & CAMPBELL, G. R. (1995) · Cited by 2,552
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 2,016
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Interleukin-17 and Type 17 Helper T Cells
Miossec, P., Korn, T., & Kuchroo, V. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0707449 · Cited by 1,409
Schwab, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,241
Diagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R. W., Fevery, J., Kalloo, A. N., Nagorney, D. M., Boberg, K. M., Shneider, B. L., & Gores, G. J. (2009) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,230
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Self-citationLindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Cited by
Sorted by citations
Ghonem, N. S., Assis, D. N., & Boyer, J. L. (2015) · Hepatology · doi:10.1002/hep.27744 · Cited by 317
Primary biliary cholangitis: pathogenesis and therapeutic opportunities
Gulamhusein, A. F., & Hirschfield, G. M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0226-7 · Cited by 308
Self-citationEllagic acid: Pharmacological activities and molecular mechanisms involved in liver protection
García‐Niño, W. R., & Zazueta, C. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.04.008 · Cited by 279
Quinn, M., McMillin, M., Galindo, C., Frampton, G., Pae, H. Y., & DeMorrow, S. (2014) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.01.159 · Cited by 259
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. E. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 236
Metadata
- Authors
- Hirschfield, G. M., Heathcote, E. J., & Gershwin, M. E.
- Affiliations
- University of Toronto (CA)
- University of California, Davis (US)
- Corresponding author
- Gershwin, M. Eric
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2010-11
- Volume
- 139
- Issue
- 5
- Pages
- 1481-1496
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2079853302
- Cited by
- 287
- References
- 187
- Citations by year
- 2026: 15 · 2025: 20 · 2024: 21 · 2023: 21 · 2022: 16 · 2021: 19 · 2020: 21 · 2019: 16 · 2018: 19 · 2017: 17 · 2016: 14 · 2015: 14 · 2014: 21 · 2013: 16 · 2012: 21
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (MOP74621)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 39588)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- cholestatic liver disease, pathogenesis, cholangiocytes, bile acid transport, cholestasis, bile duct injury, hepatocyte injury, tissue repair, apoptosis, blood supply, immune regulation, autoimmunity, genetic disorders, treatment options
- MeSH terms
- Animals, Bile, Cholagogues and Choleretics, Cholestasis, Humans, Immunity, Cellular, Immunosuppressive Agents, Liver Cirrhosis, Biliary, Prognosis, Risk Factors, Ursodeoxycholic Acid, Cytokines, Apoptosis, Hepatocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
